Werewolf Therapeutics (HOWL) Key Ratios

$0.97

$0.02 (2.38%)

As on 04-Sep-2026 16:21EDT

Market cap

$47 Mln

Revenue (TTM)

$21 Mln

P/E Ratio

--

P/B Ratio

2.9

Div. Yield

0 %

Key Ratios and Highlights

Growth Score (%)	Quarterly		Annual (TTM)
Particulars	QoQ	YoY	1-Year	3-Years	5-Years
Revenue	--	--	--	-5.39	--
EBIT	170.18	151.18	62.29	10.67	3.60
Net Profit	127.12	120.41	52.68	4.91	-1.82
EPS	127.56	118.89	55.28	12.52	11.11
Book Value	--	--	-67.89	-48.94	-44.37

Key Ratios (%)	Average		Annual (TTM)
Particulars	3-Years	5-Years	TTM	Dec-25	Dec-24
EBIT-Margin	-1,832.74	-1,303.69	-122.23	--	-3,493.85
Net Margin	--	-723.48	-164.82	--	--
Return on equity	-77.40	-62.16	-168.45	-123.88	-76.33
Return on Capital	-53.49	-46.49	--	-84.06	-51.51
Return on Assets	-43.67	-39.50	-49.53	-61.96	-46.74
Debt to Equity (x)	--	--	0.00	0.38	0.51

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	-84.06	-51.51	-24.89	-33.76	-38.25
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROE

-168.45

Lower than Peers by 128.05

Profit after tax / Average Net worth * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	-168.45	-123.88	-76.33	-31.98	-37.48	-41.13
Peer Median	-40.40	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROA

-49.53

Lower than Peers by 18.56

Profit after tax / Average Total assets * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	-49.53	-61.96	-46.74	-22.30	-30.38	-36.11
Peer Median	-30.98	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Margin

-122.23

Lower than Peers by 38.61

Operating profit (EBIT) / Net Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	-122.23	--	-3,493.85	-171.63	-341.78	-1,207.50
Peer Median	-83.62	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Margin

-164.82

Lower than Peers by 72.15

Net profit / Total Income (Net sales plus other income) * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	-164.82	--	-3,740.85	-187.37	-276.53	-1,170.44
Peer Median	-92.67	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	0.00	--	--	--	--	--
Peer Median	0.00	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	-1.00	-0.91	0.22	2.95	--
Peer Median	53.95	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Growth

62.29

Higher than Peers by 63.09

Year on year growth in operating profit (EBIT)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	62.29	15.66	-92.41	38.94	-11.92	-233.03
Peer Median	-0.80	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Profit Growth

52.68

Higher than Peers by 59.98

Year on year growth in profit after tax

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	52.68	13.75	-88.70	27.53	-3.61	-233.13
Peer Median	-7.30	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EPS Growth

55.28

Higher than Peers by 40.63

Year on year growth in earnings per share

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	55.28	0.18	-0.55	0.39	0.08	-0.10
Peer Median	14.65	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Book Value Growth

-63.63

Lower than Peers by 53.45

Year on year growth in book value per share

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	-63.63	--	--	--	--	--
Peer Median	-10.18	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	0.38	0.51	0.47	0.12	0.10
Peer Median	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	0.07	0.02	0.07	0.02	0.01
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Current Ratio

2.91

Lower than Peers by 2.90

Current Assets / Current Liabilities and Provisions

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	2.91	1.62	7.45	7.14	5.84	13.56
Peer Median	5.81	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Quick Ratio

2.91

Lower than Peers by 2.78

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	2.91	--	--	--	5.84	--
Peer Median	5.70	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Interest Coverage

-6.60

Lower than Peers by 4.51

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	-6.60	-10.53	-14.14	-10.90	-50.78	-231.88
Peer Median	-2.09	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	--	--	6.77	42.24	--
Peer Median	19.14	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Asset Turnover

0.30

Higher than Peers by 0.24

Sales / Average Total Assets

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	0.30	--	0.01	0.12	0.10	0.03
Peer Median	0.06	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Receivable days

--

--

Average Debtors / Sales * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	--	261.58	75.80	154.29	--
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Inventory Days

--

--

Average Inventory / Sales * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	--	--	0.00	0.00	--
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	423.48	440.05	264.72	237.05	759.82
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	--	--	-188.92	-82.76	--
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	-0.49	-0.93	-3.78	-1.22	-6.53
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Price / Book Value

2.85

Lower than Peers by 2.33

Current share price divided by book value per share in the latest financial year

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	2.85	1.20	0.90	1.27	0.52	2.13
Peer Median	5.18	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	--	--	--	--	--	--
Peer Median	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EV/EBITDA

0.57

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	0.57	0.35	0.13	-1.81	0.94	-3.67
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Market Cap

47

Lower than Peers by 99

Current Share price multiplied by latest total number of shares outstanding

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Werewolf Therapeutics (HOWL)	47	--	--	--	--	--
Peer Median	146	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly